Category: AtriCure Inc.
The FDA grants an investigational device exemption for an AtriCure study of patients with non-paroxysmal atrial fibrillation.
AtriCure (NSDQ:ATRC) said it won an investigational device exemption from the FDA for a 1st-of-its-kind clinical trial involving patients with non-paroxysmal atrial fibrillation.
AtriCure gets some Wall Street love after again boosting its full-year expectations on the back of a 30% boost in revenues in its 2nd quarter.
Ohio-based AtriCure (NSDQ:ATRC) gained a few points today as investors reacted to new of the company's Q2 financial report.
AtriCure's 1st-quarter sales rise 28% and beat expectations on Wall Street, prompting it to boost its revenue guidance for the rest of the year.
AtriCure (NSDQ:ATRC) boosted its 1st quarter sales above Wall Street's forecast, posting nearly 28% growth, and raised its outlook on revenues for the rest of the year.
Hedge fund giant BlackRock boosted its stake in a number of medical device companies last year, but cut its holdings in others, regulatory filings show.
Wright Medical Group Inc.
, Align Technology Inc.
, ArthroCare Corp.
, AtriCure Inc.
, Biolase Technology Inc.
, BlackRock Inc.
, Cutera Inc.
, Cynosure Inc.
, Dentsply International Inc.
, HeartWare International Inc.
, ICU Medical Inc.
, Medical Action Industries Inc.
, Merit Medical Systems Inc.
, NxStage Medical Inc.
, Thoratec Corp.
AtriCure's report of strong sales growth for the 4th quarter and 2013 sends share prices up on Wall Street.
Fresh off of the $34 million acquisition of Estech, AtriCure (NSDQ:ATRC) reported strong sales growth for the 4th quarter and 2013 and predicted even better gains for this year, sending share prices up today on Wall Street.
AtriCure offers $34 million up-front in stock for surgical ablation devices maker Estech, with another $26 million tied to performance-based milestones.
AtriCure (NSDQ:ATRC) signed a definitive agreement with Estech, offering to give the ablation devices maker about $34 million in stock.
AtriCure says the FDA granted an investigational device exemption for a clinical trial of its AtriClip left atrial appendage exclusion device to gauge its utility in preventing stroke in patients with atrial fibrillation.
AtriCure (NSDQ:ATRC) said today that the FDA approved the launch of a clinical trial to examine whether its AtriClip device can be used to prevent strokes in patients with atrial fibrillation.